View DCT Insights and Spotlights from the DTRA 2023 Annual Meeting.
The 2023 Annual Meeting
The 2023 DTRA Annual Meeting (November 5-8, 2023) convened leaders that are advancing the global adoption of decentralized research. Sessions focused on signals from regulatory and government organization to adopt these methods, progress to stabilize decentralized research, as well as updates on DCT adoption within leading biopharmaceutical companies and academic organizations.
We look forward to bringing our members together again in November 2024, at the Encore Boston Harbor.
The Fireside Chat with Deputy Director of Oncology for the FDA helped demystify the belief that oncology trials cannot utilize DCTs.
- Optionality/choice to maintain data quality in Clinical Trials
- FDA draft guidance feedback
- Learnings on what is working/not working in oncology DCTs
- What will drive community to commit/invest
A View From Washington: Driving Decentralized Research in the US Research Ecosystem
This panel included perspectives from Christopher Hartshorn (NIH/NCATS), Stephen Konya (ONC), Timil Patel (FDA), Gina Conenello (BARDA), and Anindita Shah (FDA)The US federal government has made an unprecedented commitment to decentralized trials for support representation and resilience for the nation's research infrastructure.
Hear from Rose Anderson and Rebecca Kottschade from the Mayo Clinic around their Decentralized Clinical Trials Initiative: Clinical Trials Beyond Walls
Fireside Chat with Regulatory Authorities
Dr. Leonard Sacks (FDA) and Dr. Marten Wendt (Swedish Medicines Agency) took the stage and joined Rasika Kalamegham (Roche, Head of DTRA Regulatory Forum) for a great discussion around the EMA Reflection Paper and FDA Draft Guidance and any key themes and ideas that have come to light since publication.
Learn more about Eisai's Approach to Decentralized Trials from Shobha Dhadda, Chief Clinical Science and Operations Officer, Clinical Development for Eisai.
Hear from Shelly Barnes, Global Innovation Lead at UCB talk about their number one driver to adoption and global implementation across their portfolio.
Our Pharma Spotlight Presentations featured DTRA Members sharing their DCT Journeys, including:
Erica Lawson from Otsuka joined us to share about their first fully virtual trial and the lessons learned along the way.
Jeremy Price from Pfizer joined us to discuss the Pfizer Pledge of getting 60% remote trials across all therapeutic areas in 2022.
Hassan Kadhim from Bristol Myers Squibb shared their journey to climb the DCT mountain and what we can anticipate coming next.
Kim Hawkins from Sanofi discussed how they are disrupting the clinical trial process through DCTs.
Registrants of the 2023 DTRA Annual Meeting can review recorded sessions in the Meeting App now.